Investigators concluded, “Results from this observational study suggest an association between treatment with THC-predominant cannabis flowers and symptomatic improvement for up to six months.”
Archives: News Releases
Since 1992, every Thursday and when breaking news warrants, NORML | The NORML Foundation have been issuing weekly press releases for marijuana law supporters and the media.
NORML’s News Releases archives goes back to 1996 and serves as a valuable tool to alert citizens about cannabis-related news and legislation as well as a research tool for reviewing a chronology of marijuana law reform.
“Cannabis-based products for medicinal use … can improve musculoskeletal, somatic, and psychiatric symptoms in patients with fibromyalgia,” the study’s authors determined.
“Among participants with anxiety and/or depression and pre-existing sleep problems at baseline, using cannabis … was associated with fewer sleep problems at follow-up,” researchers reported.
“This study shows that treatment with CBD-rich oil is effective and safe for patients with neuropsychiatric symptoms secondary to Alzheimers.”
Investigators found “no statistically significant associations between a history of regular cannabis smoking … and the prevalence of carotid calcified plaque.”
Pain patients also experienced “a notable decline in their use of both prescription and over-the-counter pain medications” following their use of medical cannabis.
“Cannabis users had lower rates of opioid utilization compared to non-cannabis users as early as two months after fusion [surgery],” researchers determined.
Pollsters also reported that most Canadians purchase “all” of their cannabis products from legal retailers.